MetaCap

Nasus Pharma (NSRX) vs Telomir Pharmaceuticals (TELO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nasus Pharma (NSRX) has outperformed Telomir Pharmaceuticals (TELO) over the past year, losing 68.4% versus a loss of 71.6%. Nasus Pharma is the larger company by market cap ($26.8 million vs $26.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NSRX-68.41%TELO-71.56%
+31%-23%-77%
Nov 21, 20251 yearNov 20, 2026
NSRX-71.73%TELO-75.57%
+15%-32%-80%
Aug 11, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NSRX versus TELO key metrics
MetricNSRXTELO
Share price$2.29$0.364
Market cap$26.82M$26.82M
1-day change-10.20%-17.24%
YTD return-74.97%-72.63%
1-year return-68.41%-71.56%
EPS (TTM)$-1.20$-0.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.24B—
Net income (latest FY)$-5.86M$-10.41M
Operating margin-0.40%—
Net margin-0.47%—
52-week high$9.50$1.58
52-week low$1.98$0.353
Distance from 52-week high-75.89%-76.96%
Analyst consensusbuynone
Avg. price target upside+758.95%+998.90%
Average volume16.80K126.14K
Shares outstanding11.71M73.68M
Employees7—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Nasus Pharma

NSRX stock →

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Telomir Pharmaceuticals

TELO stock →

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.

Health Care · Biotechnology: Pharmaceutical Preparations

NSRX vs TELO FAQ

Which is bigger, Nasus Pharma or Telomir Pharmaceuticals?

Nasus Pharma (NSRX) is larger, with a market capitalization of $26.82M compared with $26.82M for Telomir Pharmaceuticals (TELO).

Which stock has performed better over the past year, NSRX or TELO?

NSRX returned -68.41% over the past 12 months, compared with -71.56% for TELO (price return, excluding dividends). Past performance does not predict future results.

Are Nasus Pharma and Telomir Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons